Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.
Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP), due September 07, 2022
Open Date (Earliest Submission Date): September 07, 2022
Expiration Date: May 08, 2025
The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.
This Notice also encourages applications to develop once-a-month SR/LA strategies for treatment of latent TB and hepatitis B
Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed), due 06/08/2022
Open Date (Earliest Submission Date): May 08, 2022
Expiration Date: June 09, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to advance research to discover and validate novel biomarkers of Tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.
Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed), due 07/08/2022
Open Date (Earliest Submission Date): June 08, 2022
Expiration Date: July 09, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point of care (POC) DST and companion diagnostics for new TB drugs.
Brazil Regional Prospective Observational Research in Tuberculosis (RePORT) (U01 Clinical Trial Not Allowed)
Application open date: November 08, 2021
Expiration Date: December 09, 2021
The purpose of this Funding Opportunity Announcement (FOA) is to support a Brazil-US Regional Prospective Observational Research in Tuberculosis (RePORT) network to advance TB and TB/HIV science. The RePORT Brazil network will leverage and build upon Brazilian cohorts currently following adult and pediatric populations with active TB disease and their contacts or other high TB-risk individuals to address key research questions of regional and global interest. Specific areas supported under this program include, but are not limited to, research and development projects in TB/HIV in the areas of molecular epidemiology, diagnostics, biomarkers, vaccine development, and the impact of co-morbidities such as HIV and diabetes. Research outcomes should be capable of advancing tools with public health impact or of influencing decision making in TB public health to inform stakeholders on the best practices for early prevention, diagnosis, and clinical management of TB and TB/HIV.
Click here for more information about this funding opportunity!
Solicitation for BAA-DAIT-75N93021R00008 entitled, "Advancing Vaccine Adjuvant Research for Tuberculosis (TB)"
Contract Opportunity Type: Solicitation
The goal of this program is to further the development of TB vaccines through sideby-side comparisons of adjuvants in combination with TB immunogens, and to establish immunological profiles of adjuvants that work through different mechanisms, facilitating the identification of the most promising adjuvant:Mtb immunogen candidates for clinical development and potential immune correlates of protection. The range of adjuvants to be evaluated may include novel classes of adjuvants being developed for other infections and immune-oncology therapeutics, as well as adjuvants already being developed for TB vaccines. It is anticipated that one cost reimbursement, completion type contract will be awarded for a five -year period of performance beginning on or about 7/22/22.
NIAID anticipates that the average annual total cost (direct and indirect costs combined) is $4 million per contract. However, it is anticipated that the total cost for the award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. In no event shall the period of performance proposed by an offeror exceed five  years. Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on/about April, 28, 2021, and may be accessed through here. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.
Published: Apr 28, 2021 12:41 pm EDT
Offers Due: Aug 10, 2021 03:00 pm EDT
Post-Doctoral Research Fellowships for Global HIV and TB Public Health Programs
The mission of this fellowship program is to recruit, mentor, and train scientist-practitioners to conduct global HIV and TB research and to develop the translational and applied skills necessary to implement and support high-quality HIV and TB public health programs in global settings. The goal of this fellowship is to attract and support recent recipients of doctoral degrees to understand the underpinnings of interventional epidemiology and to prepare them for a career operating at the intersection of science and practice in global public health. The selected candidates will be in the Division of Global HIV & TB (DGHT) at the Centers for Disease Control and Prevention (CDC), headquartered in Atlanta, GA. The DGHT Office of the Director (DGHT OD) is the lead for the program. Fellows will also be paired with DGHT’s programmatic or data branches on various projects throughout their fellowship.
The deadline to apply to this fellowship is June 30, 2021. The fellowship is scheduled to begin Fall 2021, subject to availability of funds.
Click here for more information about this fellowship!
Application Due Date: Pending
The goals of this planned award are:
1) to stimulate the development and implementation of new tools and approaches to accelerate the prevention, detection and management of tuberculosis in adults and children and
2) strengthen local capacity to design, implement, disseminate and use findings from TB research.
Anticipated Award Date: 9/30/2021
Application Due Date: June 15, 2021
The purpose of this Funding Opportunity Announcement (FOA) is to solicit meritorious applications for the Tuberculosis Research Advancement Centers (TRACs) program. The main goal of these centers is to provide administrative and shared research support to foster and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to New Investigators. TRACs will provide core facilities, services and mentoring opportunities to achieve the goals of the program.
Using Syndemics to Understand HLBS Disease Emergence and Progression in People with HIV (PWH)(R01 Clinical Trial Not Allowed), expires 12/15/2021
Application Due Date(s): January 11, 2021, and December 14, 2021
This funding opportunity announcement is intended to support research project grant (R01) applications that propose to utilize a syndemics (synergistic epidemic) framework to elucidate the role of social, economic, environmental, behavioral, structural, psychological factors in promoting the synergistic interactions and clustering of heart, lung, blood, and sleep (HLBS) comorbidities among people with HIV at the population level. The ultimate goal is to identify strategies that foster holistic approaches in the clinical management of people living with HIV who have HLBS comorbidities, and to utilize existing data to assess the feasibility and cost-effectiveness of such approaches.
Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed), expires 02/23/2021
Application Due Date(s): February 22, 2021, All applications are due by 5:00 PM local time of applicant organization.
To support research to better define the role of the granuloma, the hallmark structure of pulmonary tuberculosis (TB), in TB disease and disease outcomes. Improved understanding of the granuloma will provide a much-needed knowledge base for the development of improved therapeutic approaches.